Frequency of acute vasodilator response (AVR) in incident and prevalent patients with pulmonary arterial hypertension: Results from the pulmonary vascular disease phenomics study.
Mario Naranjo, Erika B Rosenzweig, Anna R Hemnes, Miriam Jacob, Ankit Desai, Nicholas S Hill, A Brett Larive, J Emanuel Finet, Jane Leopold, Evelyn Horn and 7 more
Article in Pulmonary circulation, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04071327 (Pulmonary Hypertension Association Registry), which is not on this map. Cited by 4 papers.
0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.6field-weighted citation impact, top 16% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
17 authors at 9 institutions in 1 country.
Mario NaranjoDivision of Pulmonary and Critical Care Medicine, Department of Medicine Johns Hopkins University Baltimore Maryland USA.ORCID 0000-0001-7584-2489
Erika B RosenzweigDepartment of Pediatrics and Medicine Columbia University New York New York USA.
Anna R HemnesDivision of Allergy, Pulmonary and Critical Care Medicine Vanderbilt University Medical Center Nashville Tennessee USA.
Miriam JacobDepartment of Cardiovascular Medicine Cleveland Clinic Cleveland Ohio USA.
Ankit DesaiDepartment of Medicine, College of Medicine The University of Arizona Tucson Arizona USA.
Nicholas S HillDivision of Pulmonary, Critical Care, and Sleep Medicine Tufts Medical Center Boston Massachusetts USA.ORCID 0000-0002-8242-8339
A Brett LariveDepartment of Quantitative Health Sciences Cleveland Clinic Cleveland Ohio USA.
J Emanuel FinetDepartment of Cardiovascular Medicine Cleveland Clinic Cleveland Ohio USA.
Jane LeopoldDepartment of Cardiovascular Medicine, Brigham and Women's Hospital Harvard University Boston Massachusetts USA.
Evelyn HornDivision of Cardiology Weill Cornell University New York New York USA.
Robert FrantzDepartment of Cardiovascular Medicine Mayo Clinic Rochester Minnesota USA.ORCID 0000-0003-4128-3978
Franz RischardDepartment of Medicine, College of Medicine The University of Arizona Tucson Arizona USA.
Serpil ErzurumDepartment of Inflammation and Immunity Cleveland Clinic Cleveland Ohio USA.
Gerald BeckDepartment of Quantitative Health Sciences Cleveland Clinic Cleveland Ohio USA.
Stephen C MathaiDivision of Pulmonary and Critical Care Medicine, Department of Medicine Johns Hopkins University Baltimore Maryland USA.
Paul M HassounDivision of Pulmonary and Critical Care Medicine, Department of Medicine Johns Hopkins University Baltimore Maryland USA.
PVDOMICS Study Group
Cleveland Clinic · USJohns Hopkins University · USUniversity of Arizona · USBrigham and Women's Hospital · USColumbia University · USCornell University · USMayo Clinic · USTufts Medical Center · USVanderbilt University Medical Center · US
Funding
Pulmonary Vascular Disease Phenomics Program (PVDOMICS) Data Coordinating CenterU01HL125177 · NHLBI · CLEVELAND CLINIC LERNER COM-CWRU · PI BECK, GERALD J, ERZURUM, SERPIL C. · 2014 to 2020
$20.0M
Intergrated Endothelial Phenotyping to Redefine Pulmonary HypertensionU01HL125215 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI LEOPOLD, JANE A, WAXMAN, AARON B · 2014 to 2018
$1.7M
PVDOMICS Defining the Future Fingerprints of Pulmonary Vascular DiseaseU01HL125218 · NHLBI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI BERMAN-ROSENZWEIG, ERIKA S., HORN, EVELYN · 2014 to 2018
$1.6M
Redefining Pulmonary Hypertension through Pulmonary Vascular Disease Phenomics: Clinical Centers (CC) (U01).U01HL125205 · NHLBI · MAYO CLINIC ROCHESTER · PI FRANTZ, ROBERT PAUL · 2014 to 2018
$1.5M
A molecular phenotype of combined pulmonary hypertensionU01HL125212 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI HEMNES, ANNA R, NEWMAN, JOHN HUGHES · 2014 to 2018
$1.5M
Phenomic and genomic study to subphenotype Hispanics with pulmonary hypertensionU01HL125208 · NHLBI · UNIVERSITY OF ARIZONA · PI GARCIA, JOE G. N., RISCHARD, FRANZ P · 2014 to 2018
$1.5M
Hopkins Clinical Center for Pulmonary Vascular Disease Phenomics ProgramU01HL125175 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI HASSOUN, PAUL M., MATHAI, STEPHEN C · 2015 to 2019
$1.1M
Novel Biomarkers of Right Ventricular Dysfunction in Pulmonary Arterial HypertensionF32HL159917 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI NARANJO TOVAR, MARIO · 2022 to 2022
The prevalence of acute vasodilator response (AVR) to inhaled nitric oxide (iNO) during right heart catheterization (RHC) is 12% in idiopathic pulmonary arterial hypertension (IPAH). AVR, however, is reportedly lower in other disease-associated pulmonary arterial hypertension (PAH), such as connective tissue disease (CTD). The prevalence of AVR in patients on PAH therapy (prevalent cases) is unknown. We sought to determine AVR prevalence in Group 1 PH in the PVDOMICS cohort of incident and prevalent patients undergoing RHC. AVR was measured in response to 100% O
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Frequency of acute vasodilator response (AVR) in incident and prevalent patients with pulmonary arterial hypertension: Results from the pulmonary vascular disease phenomics study. · full record | OpenQuestion